Biotech Investor Avtar Dhillon Bets on Canadian Cannabis Producer Emerald Health

Bin Huang Emerald Health
Dr. Bin Huang, CEO of Emerald Health

Blogger Marc Davis profiled Emerald Health (TSXV: EMH) (OTC: TBQBF) recently, discussing the strategy of its Executive Chairman, Dr. Avtar Dhillon, who is building a business focused on medical cannabis but preparing for full legalization ahead.  CEO Dr. Bin Huang adds to the strength of the management team by bringing her R&D experience.

We have a strong focus on pharmaceutical formulations. And we’ve assembled a team which has deep expertise in the pharmaceutical industry. They will be using developmental protocols from the pharmaceutical industry to help change attitudes about cannabis in the medical community.

Avtar-Dhillon-Emerald-HealthDr. Avtar Dhillon, Executive Chairman of Emerald Health

We also have the ability to carry out in-house clinical trials to demonstrate the efficacy of our cannabinoid-based pain drug candidates. Ultimately, we’re aiming to innovate standardized pharmaceutical dosage medication in a pill or capsule format.

Read Marc Davis’ “Modern Medicine Needs Pot In A Pill”: http://www.huffingtonpost.ca/marc-davis-/modern-medicine-marijuana-pill_b_14135858.html

Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter